Fundraising FoxGlycosbio
Houston, US · Delaware corporation · 5 known investors
Find your way into Glycosbio
Sign up to see every warm intro you have to Glycosbio
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Glycosbio team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
GlycosBio conducts research and development using engineered lipid technologies to improve the bioavailability and therapeutic performance of natural bioactive molecules, including approaches targeting the intestinal, pulmonary, and skin microbiota. It works with clients on collaborative R&D, clinical validation, and IP licensing of its patented technologies, with research based at the Texas Medical Center in Houston.
Founders & leadership
Board
Investors · 5
How we know: Gideon Hixon Fund's portfolio page · Not right? Tell us
How we know: Green Park & Golf Ventures's portfolio page · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$2.4M disclosed across 3 rounds · 2016–2024
▶$1.1MraisedMar 2024 · 5 investors · BiotechnologyRule 506(b)
- Victoria NiklasDirector
- John ReplogleDirector
- Richard C. Jr. CilentoExecutive Officer, Director
- Frank FosterDirector
- Joseph WalowskiDirector
- Offering amount
- $5M
- Amount sold
- $1.1M
- Minimum investment
- $25K
- First sale
- Mar 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$425KraisedApr 2023 · 3 investors · BiotechnologyRule 506(b)
- Joseph WalowskiDirector
- Victoria NiklasDirector
- Richard C. Jr. CilentoExecutive Officer, Director
- Dan WatkinsDirector
- Frank FosterDirector
- Offering amount
- $1M
- Amount sold
- $425K
- Minimum investment
- $25K
- First sale
- Mar 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$829.8KraisedJan 2017 · 15 investors · Other TechnologyRule 506(b)
- Frank FosterDirector
- Richard C. CilentoExecutive Officer, Director
- Steve JurvetsonDirector
- Offering amount
- $930K
- Amount sold
- $829.8K
- Minimum investment
- $8K
- First sale
- Dec 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 1
Companies working in the same space as Glycosbio.
Frequently asked questions
- What does Glycosbio do?
- GlycosBio conducts research and development using engineered lipid technologies to improve the bioavailability and therapeutic performance of natural bioactive molecules, including approaches targeting the intestinal, pulmonary, and skin microbiota. It works with clients on collaborative R&D, clinical validation, and IP licensing of its patented technologies, with research based at the Texas Medical Center in Houston.
- Who are Glycosbio's investors?
- Glycosbio's investors include Gideon Hixon Fund, Green Park & Golf Ventures, Texas HALO Fund, Future Ventures, Mercury Fund.
- How much funding has Glycosbio raised?
- Glycosbio has disclosed $2.4M raised across 3 rounds.
- Where is Glycosbio headquartered?
- Glycosbio is headquartered in Houston, US.